PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.

Recent developments in the health sector highlight diverse changes from drug pricing initiatives by Bristol Myers and Pfizer ...

An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to ...

Australia ‘undervalues’ the products of drug companies, Pfizer has told the Productivity Commission, echoing US lobbyists ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

A recalled sickle cell drug is drawing new scrutiny from attorneys who say it may have done more harm than good, possibly ...

Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs ...

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...

Pfizer has received approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control ...

With the rise of advanced simulation and model-informed drug development (MIDD) techniques like digital twins, researchers ...

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

Pharmaceutical giants introduce an insurance-free pathway for top anticoagulant Eliquis, following similar direct-to-patient models from Eli Lilly and Novo Nordisk.